ArticleJournal of psychoactive drugs2025
Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.
Article in Journal of psychoactive drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis.Addiction (Abingdon, England) · 2026Article
- Content Analysis of Derived Intoxicating Cannabis Vape Product Attributes and Marketing In an Online Retail Environment.Substance use & misuse · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Given the rapid expansion of the derived intoxicating cannabis product (DICPs) market and product diversity, this study assessed marketing information provided by online retailers regarding specific DICP compounds. In May 2023, we searched "buy delta thc" in Google's incognito, selected the 20 most trafficked online retailers, and assessed product descriptions and related marketing claims across DICP compounds. 18/20 websites provided descriptions for various DICPs. The top five themes were psychoactive/intoxicating profile (100% of the 18 sites), physical effects (94%), mental effects (94%), naturalness (83%), and safety recommendations (83%). All DICPs, except for THCA and HHC-O, were described as psychoactive/intoxicating; potency was often discussed in relation to delta-9 or delta-8 THC. Claims related to physical effects included improvements to general health, pain management, sleep/insomnia aid (mostly for delta-9 THC). Each compound was described on at least 1 website as having relaxing/calming effects; all compounds except for THCP were described as having anti-anxiety effects. Safety recommendations included buying from trusted/reputable sources; 12 websites mentioned compounds "suitable for new users" (deltas-8,9,10 THC, HHC, THCP, THCV). Findings highlight potentially misleading information in DICP marketing and the need for stricter regulatory oversight, as well as required health warnings to protect and educate consumers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.